Genmab — Januar 2019
-
Helge 10.25. Med det luk som US havde overall, og Nbi op med + 5.10. Tjaae, - det burde give pæne stigninger mandag. Men shorterne slipper jo normalt ikke et såret offer uden kamp.
- En stor deal eller et godt bud, !! - ja så tror jeg de trækker sig. Men , synes vi er i en rimelig optrend. -
God morgen.
-
Man sidder og håber på besked fra Genmab i sin mail box
-
At JnJ har oplyst at 2mia $ er nået og stor milestone
-
-
Syros also announced today that it has made a portfolio prioritization decision not to pursue further development of SY-1425 in combinationwith daratumumab beyond completion of the ongoing pilot cohort in the Phase 2 trial. https://www.marketwatch.com/press-release/syros-announces-strategic-priorities-and-expected-milestones-2019-01-06
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind